46) Occasion-specific cognitive function is measured by |
47) explore the relationship between occasion-specific cognitive function and stroke. |
48) t the hypothesis that these children have specific cognitive deficits as opposed to |
49) l performance, indicating the presence of specific cognitive deficits. |
50) mpal atrophy may help explain deficits of specific cognitive functions in MS patient |
51) ks and stimuli that allow them to examine specific cognitive processes linked to inc |
52) The expression of cardiac-specific genes Gata4 and Mef2c and protein |
53) iation medium, expression of cardiac cell-specific genes and beating cardiomyocytes |
54) induced EnSCs to express urothelial cell-specific genes and proteins. |
55) to look at the basal expression levels of specific genes in multipotent stem cells b |
56) tional modifications in the regulation of specific genes related to processes underl |
57) Later we tested urothelium-specific genes and proteins (uroplakin-Ia, |
58) acterized for their aerodynamic diameter, specific surface area (cm(2)/g) and fine p |
59) ic diameter of 4.58 μm, FPF of 66% and specific surface area of 6302.99 cm(2)/g |
60) The specific surface area of PGMA nanobeads wa |
61) The specific surface area of the mPHEMA nanosp |
62) activity and capability due to their high specific surface areas and nanosize effect |
63) lated, counted and characterized by their specific surface marker profile 2 and 24 |
64) gely correlated with the FMD virus (FMDV)-specific antibodies. |
65) ive in a first survey in spring 2012, SBV-specific antibodies were detected in almos |
66) herds were tested for the presence of SBV-specific antibodies. |
67) though the clinical significance of donor-specific antibodies is far from being esta |
68) Here we used specific antibodies against N-acetylaspart |
69) This effect was specific for ethanol and acetaldehyde sinc |
70) europaeus agglutinin I (UEA-I), a lectin specific for human endothelium, and Griffo |
71) em, Nucleotide Diagnostic (ND) characters specific for species were identified. |
72) g-term metabolic complications, which are specific for the various bariatric procedu |
73) bodies in serum or cerebrospinal fluid is specific for this novel and widely under-d |
74) Specific phobias are among the most freque |
75) promising efficient pharmacotherapies for specific phobias consists of drugs that en |
76) be considered for patients suffering from specific phobias in case they were non-adh |
77) n of nonantidepressant pharmacotherapy of specific phobias. |
78) use of antidepressant in the treatment of specific phobias. |
add keyword